MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitiv... MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.06 | 5.26315789474 | 1.14 | 1.33 | 1.1 | 267062 | 1.20075615 | CS |
4 | 0.03 | 2.5641025641 | 1.17 | 1.5 | 1.1 | 357402 | 1.29994183 | CS |
12 | -0.4864 | -28.8425047438 | 1.6864 | 1.7499 | 0.97 | 452194 | 1.28629508 | CS |
26 | -1.15 | -48.9361702128 | 2.35 | 2.7899 | 0.97 | 1360894 | 1.75982499 | CS |
52 | 0.2861 | 31.3053944633 | 0.9139 | 5.01 | 0.51 | 1967144 | 2.83288678 | CS |
156 | -5.8 | -82.8571428571 | 7 | 7.9799 | 0.51 | 1372338 | 2.85559475 | CS |
260 | -5.8 | -82.8571428571 | 7 | 7.9799 | 0.51 | 1372338 | 2.85559475 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.